Andrew Adams

Aug 27, 2024 | onlinelibrary.wiley.com | Andrew Adams |David Faber |Brendan P. Lovasik |Abraham J. Matar

1 Introduction Developing an immunosuppressive regimen that uses clinically available drugs and consistently prolongs graft and recipient survival in preclinical models has been an elusive goal in preventing the clinical application of xenotransplantation [1-4]. Recent experience shows that successful outcomes in non-human primates (NHPs) can be achieved if the recipient level of anti-pig antibodies is low.